Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP283298.RA7HWzgrxDuOp3jAoythw6-r-C-95DXoAlCuzRG0q-CUc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP283298.RA7HWzgrxDuOp3jAoythw6-r-C-95DXoAlCuzRG0q-CUc130_assertion type Assertion NP283298.RA7HWzgrxDuOp3jAoythw6-r-C-95DXoAlCuzRG0q-CUc130_head.
- NP283298.RA7HWzgrxDuOp3jAoythw6-r-C-95DXoAlCuzRG0q-CUc130_assertion description "[The combination of IFN-gamma and CaM antagonists, including tamoxifen, may be a potential therapeutic modality for cholangiocarcinoma and possibly other malignancies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP283298.RA7HWzgrxDuOp3jAoythw6-r-C-95DXoAlCuzRG0q-CUc130_provenance.
- NP283298.RA7HWzgrxDuOp3jAoythw6-r-C-95DXoAlCuzRG0q-CUc130_assertion evidence source_evidence_literature NP283298.RA7HWzgrxDuOp3jAoythw6-r-C-95DXoAlCuzRG0q-CUc130_provenance.
- NP283298.RA7HWzgrxDuOp3jAoythw6-r-C-95DXoAlCuzRG0q-CUc130_assertion SIO_000772 14578204 NP283298.RA7HWzgrxDuOp3jAoythw6-r-C-95DXoAlCuzRG0q-CUc130_provenance.
- NP283298.RA7HWzgrxDuOp3jAoythw6-r-C-95DXoAlCuzRG0q-CUc130_assertion wasDerivedFrom befree-20140225 NP283298.RA7HWzgrxDuOp3jAoythw6-r-C-95DXoAlCuzRG0q-CUc130_provenance.
- NP283298.RA7HWzgrxDuOp3jAoythw6-r-C-95DXoAlCuzRG0q-CUc130_assertion wasGeneratedBy ECO_0000203 NP283298.RA7HWzgrxDuOp3jAoythw6-r-C-95DXoAlCuzRG0q-CUc130_provenance.